Wedbush analyst Liana Moussatos reiterated a Hold rating on Omeros Corp (OMER) today and set a price target of $18. The company’s shares closed on Friday at $18.25.
According to TipRanks.com, Moussatos is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -12.4% and a 28.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Omeros Corp with a $28.33 average price target.
See today’s analyst top recommended stocks >>
Based on Omeros Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $14.45 million. In comparison, last year the company had a GAAP net loss of $33.7 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.